Publications by authors named "Dita Strutt"

Claim this Profile
I
Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Robert Neijzen, May Q Wong, Navdeep Gill, He Wang, Tamanna Karim, Dita Strutt

J Control Release· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
Dawn N Waterhouse, Brent W Sutherland, Nancy Dos Santos, Dana Masin, Maryam Osooly, Dita Strutt

Invest New Drugs· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model.
Maite Verreault, Sherry A Weppler, Amelia Stegeman, Corinna Warburton, Dita Strutt

PLoS One· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
Nilesh A Patankar, Dawn Waterhouse, Dita Strutt, Malathi Anantha, Marcel B Bally

Invest New Drugs· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model.
Emmanuel A Ho, Maryam Osooly, Dita Strutt, Dana Masin, Youngjoo Yang

J Pharm Sci· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
Maite Verreault, Dita Strutt, Dana Masin, Malathi Anantha, Andrew Yung

BMC Cancer· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.
Euan C Ramsay, Malathi Anantha, Jason Zastre, Marieke Meijs, Jet Zonderhuis, Dita Strutt

Clin Cancer Res· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis